Compare VOR & BSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOR | BSL |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 176.1M |
| IPO Year | 2021 | N/A |
| Metric | VOR | BSL |
|---|---|---|
| Price | $13.80 | $13.57 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $66.63 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 71.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.55% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $12.19 |
| 52 Week High | $65.80 | $14.56 |
| Indicator | VOR | BSL |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 40.97 |
| Support Level | $12.05 | $13.50 |
| Resistance Level | $15.27 | $13.63 |
| Average True Range (ATR) | 1.96 | 0.06 |
| MACD | 0.65 | 0.00 |
| Stochastic Oscillator | 64.21 | 33.33 |
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.